- Home
- NUVL vs CDE Comparison
NUVL vs CDE Comparison
Compare NUVL & CDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CDE
- Stock Information
- Founded
- NUVL 2017
- CDE 1928
- Country
- NUVL United States
- CDE United States
- Employees
- NUVL N/A
- CDE N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CDE Precious Metals
- Sector
- NUVL Health Care
- CDE Basic Materials
- Exchange
- NUVL Nasdaq
- CDE Nasdaq
- Market Cap
- NUVL 5.8B
- CDE 5.7B
- IPO Year
- NUVL 2021
- CDE N/A
- Fundamental
- Price
- NUVL $81.76
- CDE $14.68
- Analyst Decision
- NUVL Strong Buy
- CDE Strong Buy
- Analyst Count
- NUVL 11
- CDE 4
- Target Price
- NUVL $120.91
- CDE $9.69
- AVG Volume (30 Days)
- NUVL 429.4K
- CDE 14.7M
- Earning Date
- NUVL 08-07-2025
- CDE 08-06-2025
- Dividend Yield
- NUVL N/A
- CDE N/A
- EPS Growth
- NUVL N/A
- CDE N/A
- EPS
- NUVL N/A
- CDE 0.39
- Revenue
- NUVL N/A
- CDE $1,459,632,000.00
- Revenue This Year
- NUVL N/A
- CDE $81.88
- Revenue Next Year
- NUVL N/A
- CDE $3.81
- P/E Ratio
- NUVL N/A
- CDE $36.35
- Revenue Growth
- NUVL N/A
- CDE 63.68
- 52 Week Low
- NUVL $55.54
- CDE $4.58
- 52 Week High
- NUVL $113.51
- CDE $14.32
- Technical
- Relative Strength Index (RSI)
- NUVL 64.02
- CDE 86.19
- Support Level
- NUVL $73.28
- CDE $11.41
- Resistance Level
- NUVL $81.10
- CDE $11.97
- Average True Range (ATR)
- NUVL 2.51
- CDE 0.48
- MACD
- NUVL 0.84
- CDE 0.19
- Stochastic Oscillator
- NUVL 92.63
- CDE 97.30
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico.